IRF8 (Interferon regulatory factor 8) variants and mutations
IRF8 (also known as Interferon regulatory factor 8) is a human protein-coding gene encoding an interferon regulatory factor 8 protein. It directs development and antimicrobial programs of monocytes, dendritic cells, and other myeloid populations and cooperates with interferon signaling. Pathogenic variants can cause immunodeficiency with abnormal monocyte or dendritic-cell development and susceptibility to mycobacterial infection. This analysis covers 746 IRF8 variants and mutations. Of these, 77% have computational variant effect predictions. Disease context includes immunodeficiency 32B, B-cell chronic lymphocytic leukemia, and lymphoid leukemia. Example IRF8 variants include C2R, C2Y, and C2C.
Variant analysis overview
- Gene: IRF8
- Protein: Interferon regulatory factor 8
- UniProt accession: Q02556
- Organism: Homo sapiens
- Variants analyzed: 746
- Variant scope: all variants
- Completed: 2026-08-20
Variant and mutation evidence
- Variant composition: 548 unspecified-consequence records; 91 missense variants; 92 synonymous variants; 7 stop-gained variants; 2 frameshift variants; 3 in-frame deletions; 2 splice-region variants; 1 substitution
- Prediction scores: 574 variants have prediction scores (77% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: immunodeficiency 32B, B-cell chronic lymphocytic leukemia, lymphoid leukemia, immunodeficiency disease, Oral ulcer, liver disorder, leukemia, plasma cell myeloma, non-Hodgkin lymphoma, Hodgkins lymphoma, Shock, systemic lupus erythematosus.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable IRF8 variants
Examples include C2R, C2Y, C2C, D3E, D3D, R4Q, R4W, R4G. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- C2R (p.Cys2Arg), gnomAD 16-85903019-T-C, REVEL 0.61, CADD 27.90
- C2Y (p.Cys2Tyr), gnomAD 16-85903020-G-A, REVEL 0.52, CADD 27.00
- C2C (p.Cys2Cys), rs374563565, gnomAD 16-85903021-T-C, CADD 14.10
- D3E (p.Asp3Glu), rs886039596, ClinGen CA10588628, ClinVar RCV000255394, Ensembl rs886039596, AlphaMissense 0.28, MetaLR 0.82, Uncertain significance, not provided
- D3D (p.Asp3Asp), gnomAD 16-85903024-C-T, CADD 11.60
- R4Q (p.Arg4Gln), cosmic curated COSV51898, ExAC rs766524400, TOPMed rs766524400, gnomAD rs766524400, REVEL 0.39, CADD 28.00, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to partial IRF8 deficienc
- R4W (p.Arg4Trp), rs1064796262, ClinGen CA16620277, ClinVar RCV000480436, TOPMed rs1064796262, REVEL 0.61, CADD 24.70, Uncertain significance, not provided
- R4G (p.Arg4Gly), gnomAD 16-85903025-C-G, REVEL 0.49, CADD 22.60
- N5S (p.Asn5Ser), Ensembl rs1834775112, REVEL 0.34, CADD 16.90, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to partial IRF8 deficienc
- N5I (p.Asn5Ile), gnomAD 16-85903029-A-T, REVEL 0.64, CADD 24.40
- G7S (p.Gly7Ser), rs201464467, ClinGen CA8216725, ClinVar RCV001991421, 1000Genomes rs201464467, REVEL 0.64, CADD 23.60, Uncertain significance, Immunodeficiency 32B; Mendelian susceptibility to mycobacterial diseases due to
- G7V (p.Gly7Val), gnomAD 16-85903035-G-T, REVEL 0.74, CADD 26.20
- R8P (p.Arg8Pro), TOPMed rs762945281, gnomAD rs762945281
- R8Q (p.Arg8Gln), cosmic curated COSV51896, TOPMed rs762945281, gnomAD rs762945281, REVEL 0.74, CADD 26.00
- R8W (p.Arg8Trp), rs1293439667, ClinGen CA397000096, ClinVar RCV001990157, gnomAD rs1293439667, REVEL 0.82, CADD 26.40, Uncertain significance, Immunodeficiency 32B; Mendelian susceptibility to mycobacterial diseases due to
- R8R (p.Arg8Arg), gnomAD 16-85903037-C-A, CADD 13.60
- R9W (p.Arg9Trp), rs759579543, ClinGen CA8216726, ClinVar RCV001297959, ExAC rs759579543, REVEL 0.91, CADD 25.50, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to partial IRF8 deficienc
- R9R (p.Arg9Arg), rs759579543, gnomAD 16-85903040-C-A, CADD 12.10
- L10P (p.Leu10Pro), gnomAD 16-85903044-T-C, REVEL 0.97, CADD 31.00
- R11* (p.Arg11Ter), NCI-TCGA Cosmic COSV5190, cosmic curated COSV51900, CADD 37.00, Variant assessed as somatic; high impact.
- R11Q (p.Arg11Gln), rs1192543113, gnomAD rs1192543113, REVEL 0.82, CADD 29.70, Variant assessed as somatic; moderate impact.
- R11R (p.Arg11Arg), rs1904876257, gnomAD 16-85903048-A-G, CADD 11.30
- Q12E (p.Gln12Glu), TOPMed rs1904876410
- Q12L (p.Gln12Leu), rs1388876338, ClinGen CA397000119, ClinVar RCV001978245, TOPMed rs1388876338, REVEL 0.90, CADD 29.30, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to partial IRF8 deficienc
- Q12Q (p.Gln12Gln), gnomAD 16-85903051-G-A, CADD 11.60
- W13G (p.Trp13Gly), Ensembl rs1597248993
- W13* (p.Trp13Ter), gnomAD 16-85903053-G-A, CADD 40.00
- L14L (p.Leu14Leu), gnomAD 16-85903055-C-T, CADD 13.60
- I15L (p.Ile15Leu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- I15M (p.Ile15Met), rs764958679, ClinGen CA397000142, ClinVar RCV001036891, ExAC rs764958679, REVEL 0.48, CADD 4.73, Uncertain significance, Immunodeficiency 32B; Mendelian susceptibility to mycobacterial diseases due to
- I15V (p.Ile15Val), Ensembl rs1597248997
- I15I (p.Ile15Ile), rs764958679, gnomAD 16-85903060-C-T, CADD 6.57
- E16G (p.Glu16Gly), gnomAD rs1452914312
- E16K (p.Glu16Lys), rs1347366121, ClinGen CA397000143, ClinVar RCV003790283, ClinVar RCV006368605, REVEL 0.79, CADD 32.00, Uncertain significance, Inborn genetic diseases; Immunodeficiency 32B; Mendelian susceptibility to mycob
- Q17E (p.Gln17Glu), gnomAD 16-85903064-C-G, REVEL 0.90, CADD 25.70
- I18T (p.Ile18Thr), gnomAD rs1173576430, REVEL 0.89, CADD 25.90, Uncertain significance, not provided
- I18D (p.Ile18Asp), gnomAD 16-85903065-A-AG, CADD 31.00
- D19G (p.Asp19Gly), rs1391251618, ClinGen CA397000170, ClinVar RCV003795304, gnomAD rs1391251618, REVEL 0.85, CADD 31.00, Uncertain significance, Immunodeficiency 32B; Mendelian susceptibility to mycobacterial diseases due to
- D19D (p.Asp19Asp), gnomAD 16-85903072-C-T, CADD 13.70
- S20G (p.Ser20Gly), rs1597249015, ClinGen CA397000176, ClinVar RCV001345765, Ensembl rs1597249015, REVEL 0.95, CADD 28.70, Uncertain significance, Immunodeficiency 32B; Mendelian susceptibility to mycobacterial diseases due to
- S20N (p.Ser20Asn), rs377070739, ClinGen CA8216729, ClinVar RCV003789937, ESP rs377070739, REVEL 0.76, CADD 28.00, Uncertain significance, Inborn genetic diseases; Immunodeficiency 32B; Mendelian susceptibility to mycob
- S20S (p.Ser20Ser), rs763711333, gnomAD 16-85903075-T-C, CADD 12.20
- S21G (p.Ser21Gly), gnomAD 16-85903076-A-G, REVEL 0.27, CADD 11.70
- S21N (p.Ser21Asn), gnomAD 16-85903077-G-A, REVEL 0.34, CADD 1.60
- S21T (p.Ser21Thr), gnomAD 16-85903077-G-C, REVEL 0.35, CADD 2.79
- S21I (p.Ser21Ile), gnomAD 16-85903077-G-T, REVEL 0.48, CADD 11.40
- S21S (p.Ser21Ser), gnomAD 16-85903078-C-T, CADD 13.10
- M22I (p.Met22Ile), cosmic curated COSV10877, TOPMed rs1396151109, gnomAD rs1396151109, REVEL 0.43, CADD 22.10, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to partial IRF8 deficienc
- M22K (p.Met22Lys), ExAC rs751261768, TOPMed rs751261768, gnomAD rs751261768, REVEL 0.42, CADD 19.60
- M22T (p.Met22Thr), ExAC rs751261768, TOPMed rs751261768, gnomAD rs751261768, REVEL 0.49, CADD 21.90
- M22R (p.Met22Arg), gnomAD 16-85903080-T-G, REVEL 0.52, CADD 22.40
- Y23C (p.Tyr23Cys), rs370086181, ClinGen CA8216732, ClinVar RCV001371444, ESP rs370086181, REVEL 0.97, CADD 31.00, Uncertain significance, Immunodeficiency 32B; Mendelian susceptibility to mycobacterial diseases due to
- Y23H (p.Tyr23His), NCI-TCGA Cosmic COSV5189, cosmic curated COSV51897, Likely oncogenic, Neoplasm
- P24A (p.Pro24Ala), rs1904878101, ClinGen CA397000204, cosmic curated COSV10509, ClinVar RCV001212056, REVEL 0.47, CADD 19.90, Uncertain significance, Immunodeficiency 32B; Mendelian susceptibility to mycobacterial diseases due to
- P24R (p.Pro24Arg), Ensembl rs1904878177, REVEL 0.79, CADD 24.40
- P24P (p.Pro24Pro), gnomAD 16-85903087-A-T, CADD 3.46
- G25* (p.Gly25Ter), NCI-TCGA Cosmic COSV9923, cosmic curated COSV99236, Variant assessed as somatic; high impact.
- G25V (p.Gly25Val), NCI-TCGA Cosmic COSV9923, cosmic curated COSV99236, Variant assessed as somatic; moderate impact.
- G25G (p.Gly25Gly), rs988591939, gnomAD 16-85903090-A-G, CADD 11.40
- L26L (p.Leu26Leu), gnomAD 16-85903091-C-T, CADD 12.70
- I27T (p.Ile27Thr), TOPMed rs914225825, gnomAD rs914225825, REVEL 0.54, CADD 23.60
- I27I (p.Ile27Ile), rs749700728, gnomAD 16-85903096-T-A, CADD 2.87
- W28* (p.Trp28Ter), gnomAD 16-85903099-G-A, CADD 38.00
- N30K (p.Asn30Lys), ExAC rs772616220, TOPMed rs772616220, gnomAD rs772616220, REVEL 0.63, CADD 11.00
- N30S (p.Asn30Ser), ExAC rs779381872, gnomAD rs779381872, REVEL 0.39, CADD 18.00
- N30T (p.Asn30Thr), ExAC rs779381872, gnomAD rs779381872, REVEL 0.54, CADD 19.30
- N30N (p.Asn30Asn), rs772616220, gnomAD 16-85903105-T-C, CADD 2.49
- E31D (p.Glu31Asp), Ensembl rs2152098672
- E31K (p.Glu31Lys), gnomAD 16-85903106-G-A, REVEL 0.43, CADD 25.20
- E31E (p.Glu31Glu), gnomAD 16-85903108-G-A, CADD 1.65
- E32D (p.Glu32Asp), NCI-TCGA Cosmic COSV5189, cosmic curated COSV51897, NCI-TCGA Cosmic COSV5190, ExAC rs747326308, REVEL 0.39, CADD 21.00, Variant assessed as somatic; moderate impact.
- E32del (p.Glu32del), rs1567875661, gnomAD 16-85903105-TGAG-, CADD 21.70
- K33R (p.Lys33Arg), rs770905943, ClinGen CA8216741, cosmic curated COSV51897, ClinVar RCV003808407, REVEL 0.54, CADD 23.00, Uncertain significance, Immunodeficiency 32B; Mendelian susceptibility to mycobacterial diseases due to
- K33T (p.Lys33Thr), gnomAD 16-85903113-A-C, REVEL 0.85, CADD 27.60
- S34N (p.Ser34Asn), rs1904879589, ClinGen CA397000273, cosmic curated COSV51898, ClinVar RCV001206359, REVEL 0.34, CADD 14.90, Uncertain significance, Immunodeficiency 32B; Mendelian susceptibility to mycobacterial diseases due to
- S34R (p.Ser34Arg), rs200775854, ClinGen CA8216742, ClinVar RCV002607674, 1000Genomes rs200775854, REVEL 0.42, CADD 22.70, Uncertain significance, Immunodeficiency 32B; Mendelian susceptibility to mycobacterial diseases due to
- S34G (p.Ser34Gly), gnomAD 16-85903115-A-G, REVEL 0.37, CADD 20.30
- M35I (p.Met35Ile), gnomAD rs1215205167, REVEL 0.49, CADD 21.30
- M35T (p.Met35Thr), rs140921131, ClinGen CA8216743, ClinVar RCV002027744, ESP rs140921131, REVEL 0.83, CADD 24.10, Uncertain significance, Immunodeficiency 32B; Mendelian susceptibility to mycobacterial diseases due to
- M35V (p.Met35Val), gnomAD rs763570356, REVEL 0.61, CADD 22.80
- M35L (p.Met35Leu), gnomAD 16-85903118-A-T, REVEL 0.40, CADD 21.00
- F36L (p.Phe36Leu), gnomAD 16-85903121-T-C, REVEL 0.96, CADD 31.00
- F36F (p.Phe36Phe), gnomAD 16-85903123-C-T, CADD 14.50
- R37Q (p.Arg37Gln), rs1250694242, NCI-TCGA Cosmic COSV5189, cosmic curated COSV51897, TOPMed rs1250694242, REVEL 0.90, CADD 32.00, Variant assessed as somatic; moderate impact.
- R37W (p.Arg37Trp), NCI-TCGA Cosmic COSV5189, cosmic curated COSV51897, Variant assessed as somatic; moderate impact.
- R37R (p.Arg37Arg), rs1467420993, gnomAD 16-85903126-G-C, CADD 12.60
- I38T (p.Ile38Thr), gnomAD 16-85903128-T-C, REVEL 0.98, CADD 28.60
- I38I (p.Ile38Ile), rs1193476444, gnomAD 16-85903129-C-A, CADD 12.20
- P39S (p.Pro39Ser), gnomAD 16-85903130-C-T, REVEL 0.98, CADD 26.20
- P39R (p.Pro39Arg), gnomAD 16-85903131-C-G, REVEL 0.97, CADD 26.70
- K41Q (p.Lys41Gln), gnomAD 16-85903136-A-C, REVEL 0.96, CADD 28.10
- K41K (p.Lys41Lys), gnomAD 16-85903138-A-G, CADD 7.83
- H42N (p.His42Asn), gnomAD 16-85903139-C-A, REVEL 0.91, CADD 25.30
- H42H (p.His42His), rs150193781, gnomAD 16-85903141-C-T, CADD 2.78
- A43T (p.Ala43Thr), gnomAD 16-85903142-G-A, REVEL 0.90, CADD 28.70
- A43S (p.Ala43Ser), gnomAD 16-85903142-G-T, REVEL 0.83, CADD 27.40
- A43G (p.Ala43Gly), gnomAD 16-85903143-C-G, REVEL 0.82, CADD 26.10
- G44S (p.Gly44Ser), rs2544996528, ClinGen CA397000341, ClinVar RCV003027722, Uncertain significance, Immunodeficiency 32B; Mendelian susceptibility to mycobacterial diseases due to
- K45K (p.Lys45Lys), rs1476703450, gnomAD 16-85903150-G-A, CADD 6.61
- Q46E (p.Gln46Glu), gnomAD 16-85903151-C-G, REVEL 0.87, CADD 24.90
- Y48Y (p.Tyr48Tyr), rs1166622622, gnomAD 16-85903159-T-C, CADD 2.14
- N49T (p.Asn49Thr), gnomAD 16-85903161-A-C, REVEL 0.68, CADD 24.90
- Q50P (p.Gln50Pro), TOPMed rs1904881225
- Q50Q (p.Gln50Gln), rs1418920342, gnomAD 16-85903165-G-A, CADD 10.20
- E51K (p.Glu51Lys), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- E51Q (p.Glu51Gln), gnomAD 16-85903166-G-C, REVEL 0.78, CADD 26.40
- D53H (p.Asp53His), gnomAD rs1167377783, REVEL 0.97, CADD 32.00
- D53Y (p.Asp53Tyr), gnomAD 16-85903172-G-T, REVEL 0.96, CADD 32.00
- A54S (p.Ala54Ser), TOPMed rs1329459790, gnomAD rs1329459790, REVEL 0.84, CADD 26.50
- A54A (p.Ala54Ala), rs1392635609, gnomAD 16-85903177-C-T, CADD 8.65
- S55A (p.Ser55Ala), NCI-TCGA Cosmic COSV5189, cosmic curated COSV51897, Variant assessed as somatic; moderate impact.
- S55Y (p.Ser55Tyr), NCI-TCGA Cosmic COSV5189, cosmic curated COSV51899, Variant assessed as somatic; moderate impact.
- S55S (p.Ser55Ser), rs1246022579, gnomAD 16-85903180-C-A, CADD 8.38
- I56V (p.Ile56Val), ExAC rs775453097, TOPMed rs775453097, gnomAD rs775453097, REVEL 0.75, CADD 22.80
- F57S (p.Phe57Ser), gnomAD 16-85903185-T-C, REVEL 0.99, CADD 27.30
- K58* (p.Lys58Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- K58E (p.Lys58Glu), TOPMed rs1364266041
- K58R (p.Lys58Arg), TOPMed rs1904882270, gnomAD rs1904882270, REVEL 0.82, CADD 33.00
- K58K (p.Lys58Lys), rs1904882373, gnomAD 16-85903189-G-A, CADD 24.40
- A59=, NCI-TCGA Cosmic COSV9923, Variant assessed as somatic; low impact.
- A59S (p.Ala59Ser), gnomAD rs1474894975, REVEL 0.85, CADD 33.00
- W60R (p.Trp60Arg), gnomAD 16-85908993-T-C, REVEL 0.95, CADD 31.00
- A61G (p.Ala61Gly), ExAC rs758991256
- A61T (p.Ala61Thr), gnomAD 16-85908996-G-A, REVEL 0.93, CADD 29.40
- V62A (p.Val62Ala), ExAC rs777937264
- V62I (p.Val62Ile), rs1597251890, ClinGen CA397000486, ClinVar RCV000818680, Ensembl rs1597251890, AlphaMissense 0.07, MetaLR 0.78, Uncertain significance, Immunodeficiency 32B; Mendelian susceptibility to mycobacterial diseases due to
- K64E (p.Lys64Glu), gnomAD 16-85909005-A-G, REVEL 0.94, CADD 29.80
- G65E (p.Gly65Glu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- G65V (p.Gly65Val), TOPMed rs1338775218, gnomAD rs1338775218, REVEL 0.93, CADD 29.50
- G65W (p.Gly65Trp), NCI-TCGA Cosmic COSV5189, NCI-TCGA Cosmic COSV5190, cosmic curated COSV51901, Variant assessed as somatic; moderate impact.
- K66N (p.Lys66Asn), ExAC rs781442460, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to partial IRF8 deficienc
- K66Q (p.Lys66Gln), ExAC rs757607650
- K66K (p.Lys66Lys), gnomAD 16-85909013-G-A, CADD 9.62
- F67L (p.Phe67Leu), ExAC rs746153058, REVEL 0.61, CADD 22.80
- E69* (p.Glu69Ter), NCI-TCGA Cosmic COSV9923, cosmic curated COSV99236, Variant assessed as somatic; high impact.
- E69D (p.Glu69Asp), ExAC rs769848729, gnomAD rs769848729, REVEL 0.54, CADD 23.10
- E69E (p.Glu69Glu), rs769848729, gnomAD 16-85909022-A-G, CADD 12.40
- G70W (p.Gly70Trp), ExAC rs780120102, gnomAD rs780120102, REVEL 0.91, CADD 32.00
- D71E (p.Asp71Glu), cosmic curated COSV51896, ExAC rs749156548, gnomAD rs749156548, REVEL 0.77, CADD 23.90
- D71N (p.Asp71Asn), gnomAD rs1402618760
- D71Y (p.Asp71Tyr), gnomAD 16-85909026-G-T, REVEL 0.91, CADD 29.90
- K72N (p.Lys72Asn), ExAC rs768669423
- A73S (p.Ala73Ser), ExAC rs761647639, TOPMed rs761647639, gnomAD rs761647639
- A73T (p.Ala73Thr), ExAC rs761647639, TOPMed rs761647639, gnomAD rs761647639, REVEL 0.74, CADD 27.60
- A73V (p.Ala73Val), rs771805067, ClinGen CA8216786, ClinVar RCV001366045, ExAC rs771805067, REVEL 0.74, CADD 24.40, Uncertain significance, Immunodeficiency 32B; Mendelian susceptibility to mycobacterial diseases due to
- E74D (p.Glu74Asp), cosmic curated COSV51896, ExAC rs79518337, gnomAD rs79518337, REVEL 0.39, CADD 14.30
- E74K (p.Glu74Lys), ExAC rs760464695, gnomAD rs760464695, REVEL 0.79, CADD 32.00
- E74Q (p.Glu74Gln), ExAC rs760464695, gnomAD rs760464695, REVEL 0.82, CADD 27.90
- P75P (p.Pro75Pro), rs1905075369, gnomAD 16-85909040-A-G, CADD 10.30
- A76V (p.Ala76Val), rs2152100693, ClinGen CA397000583, ClinVar RCV001952983, Ensembl rs2152100693, AlphaMissense 1.00, MetaLR 0.96, Uncertain significance, Immunodeficiency 32B; Mendelian susceptibility to mycobacterial diseases due to
- A76S (p.Ala76Ser), rs371252337, gnomAD 16-85909037-A-AC, CADD 29.70
- A76A (p.Ala76Ala), rs1905075433, gnomAD 16-85909043-C-T, CADD 12.90
- T77A (p.Thr77Ala), TOPMed rs922368153, gnomAD rs922368153
- T77S (p.Thr77Ser), TOPMed rs922368153, gnomAD rs922368153, REVEL 0.60, CADD 23.70
- T77N (p.Thr77Asn), gnomAD 16-85909045-C-A, REVEL 0.85, CADD 25.10
- W78R (p.Trp78Arg), rs1228770114, gnomAD 16-85909188-T-C, CADD 0.35
- W78* (p.Trp78Ter), gnomAD 16-85909189-G-A, CADD 3.02
- W78S (p.Trp78Ser), rs1253190595, gnomAD 16-85909189-G-C, CADD 2.52
- W78L (p.Trp78Leu), rs1253190595, gnomAD 16-85909189-G-T, CADD 2.27
- W78C (p.Trp78Cys), rs1905079441, gnomAD 16-85909190-G-T, CADD 4.03
- K79M (p.Lys79Met), gnomAD 16-85909051-A-T, REVEL 0.98, CADD 29.30
- T80A (p.Thr80Ala), rs397514711, ClinGen CA144516, NCI-TCGA Cosmic COSV5189, cosmic curated COSV51897, AlphaMissense 1.00, MetaLR 0.93, Likely pathogenic, Mendelian susceptibility to mycobacterial diseases due to partial IRF8 deficienc
- T80M (p.Thr80Met), NCI-TCGA Cosmic COSV5189, cosmic curated COSV51899, Variant assessed as somatic; moderate impact., in IMD32A
- T80R (p.Thr80Arg), rs1905075639, ClinGen CA397000609, cosmic curated COSV10727, ClinVar RCV001036021, AlphaMissense 1.00, MetaLR 0.95, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to partial IRF8 deficienc
- T80T (p.Thr80Thr), rs1308513542, gnomAD 16-85909055-G-A, CADD 4.86
- R81G (p.Arg81Gly), Ensembl rs1674652270
- R81K (p.Arg81Lys), UniProt VAR 036490, Uncertain significance, in a breast cancer sample
- R81P (p.Arg81Pro), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact., in a breast cancer sample
- R81S (p.Arg81Ser), gnomAD 16-85909058-G-C, REVEL 0.89, CADD 24.70
- L82* (p.Leu82Ter), TOPMed rs1333675827, gnomAD rs1333675827, CADD 40.00
- L82G (p.Leu82Gly), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- L82S (p.Leu82Ser), rs1333675827, TOPMed rs1333675827, gnomAD rs1333675827, REVEL 0.98, CADD 29.50, Variant assessed as somatic; moderate impact.
- R83H (p.Arg83His), ExAC rs763333317, gnomAD rs763333317, REVEL 0.99, CADD 32.00
- R83C (p.Arg83Cys), gnomAD 16-85909062-C-T, REVEL 0.97, CADD 29.90
- R83R (p.Arg83Arg), rs2152100701, gnomAD 16-85909064-C-T, CADD 12.90
- C84R (p.Cys84Arg), rs2545000986, ClinGen CA397000631, ClinVar RCV002304976, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to partial IRF8 deficienc
- A85V (p.Ala85Val), ExAC rs764636779, gnomAD rs764636779, REVEL 0.92, CADD 26.90
- N87D (p.Asn87Asp), gnomAD rs1348996824, REVEL 0.93, CADD 27.50
- N87S (p.Asn87Ser), gnomAD 16-85909075-A-G, REVEL 0.94, CADD 26.50
- N87N (p.Asn87Asn), rs752043668, gnomAD 16-85909076-T-C, CADD 11.10
Public IRF8 analysis runs
- IRF8 analysis run — IRF8 (746 variants) — completed 2026-08-20